This document provides a short summary of this study for a general audience. You can
find more information in the scientific summaries of the study. Links to those
summaries are provided at the end of this document.
Study names
Short Title: A study to compare a combination of umeclidinium and vilanterol with
umeclidinium alone and salmeterol alone in patients with chronic obstructive
pulmonary disease.
Full Scientific Title: A 24-week treatment, multi-centre, randomised, double-blind,
double-dummy, parallel group study to compare Umeclidinium/Vilanterol,
Umeclidinium, and Salmeterol in subjects with chronic obstructive pulmonary disease
(COPD).
Study Number: 201749
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When was this study done?
The study started in June 2017 and ended in June 2018.
What was the main objective of this study?
Chronic obstructive pulmonary disease is a long-term disease of the lungs that makes it
hard to breathe and gets worse over time. For patients with COPD, inhaled medicines
are an important part of treatment.
The main objective of this study was to compare lung function in patients with COPD
using a combination of umeclidinium and vilanterol in a single inhaler with
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when
using these data, we ask that proper credit or attribution of GSK as the source of the data be given.
GSK disclaims liability for all uses of the data by users of this Document, to the fullest extent
permitted by applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK
are waived, licensed or otherwise affected.